CY1121895T1 - Σκευασματα διαλυματος κατασκευασμενων αντισωματων anti-il-23p19 - Google Patents
Σκευασματα διαλυματος κατασκευασμενων αντισωματων anti-il-23p19Info
- Publication number
- CY1121895T1 CY1121895T1 CY20191100675T CY191100675T CY1121895T1 CY 1121895 T1 CY1121895 T1 CY 1121895T1 CY 20191100675 T CY20191100675 T CY 20191100675T CY 191100675 T CY191100675 T CY 191100675T CY 1121895 T1 CY1121895 T1 CY 1121895T1
- Authority
- CY
- Cyprus
- Prior art keywords
- solution preparations
- hum13b8
- antibody
- treatment
- concentrated solution
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title 1
- 102000013264 Interleukin-23 Human genes 0.000 abstract 1
- 108010065637 Interleukin-23 Proteins 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229940124829 interleukin-23 Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737035P | 2012-12-13 | 2012-12-13 | |
| PCT/US2013/073825 WO2014093203A1 (en) | 2012-12-13 | 2013-12-09 | SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121895T1 true CY1121895T1 (el) | 2020-10-14 |
Family
ID=50934859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100675T CY1121895T1 (el) | 2012-12-13 | 2019-06-27 | Σκευασματα διαλυματος κατασκευασμενων αντισωματων anti-il-23p19 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20150329632A1 (OSRAM) |
| EP (1) | EP2931313B1 (OSRAM) |
| JP (1) | JP6266012B2 (OSRAM) |
| KR (1) | KR102004585B1 (OSRAM) |
| CN (1) | CN104870016B (OSRAM) |
| AU (1) | AU2013359767B2 (OSRAM) |
| BR (1) | BR112015013540B1 (OSRAM) |
| CA (1) | CA2894869C (OSRAM) |
| CL (1) | CL2015001608A1 (OSRAM) |
| CY (1) | CY1121895T1 (OSRAM) |
| DK (1) | DK2931313T3 (OSRAM) |
| EA (1) | EA034616B1 (OSRAM) |
| ES (1) | ES2732861T3 (OSRAM) |
| HR (1) | HRP20191137T1 (OSRAM) |
| HU (1) | HUE045668T2 (OSRAM) |
| IL (3) | IL307581A (OSRAM) |
| LT (1) | LT2931313T (OSRAM) |
| MX (1) | MX357936B (OSRAM) |
| MY (1) | MY187921A (OSRAM) |
| NZ (1) | NZ708443A (OSRAM) |
| PE (1) | PE20151524A1 (OSRAM) |
| PH (1) | PH12015501296B1 (OSRAM) |
| PL (1) | PL2931313T3 (OSRAM) |
| PT (1) | PT2931313T (OSRAM) |
| RS (1) | RS59057B1 (OSRAM) |
| SI (1) | SI2931313T1 (OSRAM) |
| SM (1) | SMT201900414T1 (OSRAM) |
| TR (1) | TR201909584T4 (OSRAM) |
| UA (1) | UA117466C2 (OSRAM) |
| WO (1) | WO2014093203A1 (OSRAM) |
| ZA (1) | ZA201504408B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| EP3603669B1 (en) * | 2017-03-31 | 2024-06-19 | Meiji Seika Pharma Co., Ltd. | Aqueous formulation, aqueous formulation in injector, antibody protein disaggregating agent, and antibody protein disaggregation method |
| CA3092551A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
| US12036280B2 (en) | 2018-11-21 | 2024-07-16 | Regeneron Pharmaceuticals, Inc. | High concentration protein formulation |
| TWI779253B (zh) | 2018-11-27 | 2022-10-01 | 大陸商信達生物製藥（蘇州）有限公司 | 抗IL-23p19抗體及其用途 |
| MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
| AU2020226619A1 (en) * | 2019-02-20 | 2021-08-05 | Amgen Inc. | Methods of determining protein stability |
| PH12021552536A1 (en) * | 2019-04-15 | 2022-07-04 | Sun Pharmaceutical Ind Ltd | Methods for treatment of subjects with psoriatic arthritis |
| CA3138241A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| US20210070852A1 (en) * | 2019-09-09 | 2021-03-11 | Boehringer Ingelheim International Gmbh | Anti-IL-23p19 Antibody Formulations |
| KR20220143005A (ko) * | 2019-12-20 | 2022-10-24 | 노바록 바이오테라퓨틱스 리미티드 | 항-인터루킨-23 p19 항체 및 이의 사용 방법 |
| CA3178853A1 (en) * | 2020-05-13 | 2021-11-18 | Wei Cao | Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof |
| EP4596046A3 (en) | 2020-05-21 | 2025-10-22 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| WO2025071362A1 (ko) * | 2023-09-27 | 2025-04-03 | 삼성바이오에피스 주식회사 | 항-il-23 항체의 안정한 액상 제형 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3873200A (en) | 1999-03-11 | 2000-09-28 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| IL148300A0 (en) | 1999-09-09 | 2002-09-12 | Schering Corp | Mammalian cytokines; related reagents and methods |
| ATE454137T1 (de) | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| US20030138417A1 (en) * | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US20040219150A1 (en) | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
| ZA200506159B (en) | 2003-02-10 | 2006-10-25 | Elan Pharm Inc | Immunoglobulin formulation and method of preparation thereof |
| SI1601694T1 (sl) | 2003-03-10 | 2010-01-29 | Schering Corp | Uporabe IL-23 antagonistov; sorodni reagenti |
| DK1610820T4 (da) * | 2003-04-04 | 2013-11-04 | Genentech Inc | Høj-koncentration antistof- og proteinformuleringer |
| JP4903061B2 (ja) | 2004-02-17 | 2012-03-21 | シェーリング コーポレイション | Ｉｌ−２３活性を調節する方法；関連する試薬 |
| EP1755673B1 (en) | 2004-04-12 | 2014-07-23 | MedImmune, LLC | Anti-il-9 antibody formulations and uses thereof |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| PT1896073E (pt) | 2005-06-30 | 2013-05-28 | Janssen Biotech Inc | Composições, métodos e aplicações de anticorpos anti-il-23 |
| EA013506B1 (ru) | 2005-08-25 | 2010-06-30 | Эли Лилли Энд Компани | Антитело к il-23 и его применение |
| EP2354160A1 (en) | 2005-08-31 | 2011-08-10 | Schering Corporation | Engineered anti-IL-23-antibodies |
| AU2006330411B2 (en) | 2005-12-29 | 2012-07-12 | Janssen Biotech, Inc. | Human anti-IL-23 antibodies, compositions, methods and uses |
| WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| CA2666492C (en) | 2006-10-20 | 2012-07-17 | Douglas Rehder | Stable polypeptide formulations |
| CN101600457B (zh) | 2007-01-09 | 2014-01-08 | 惠氏公司 | 抗il-13抗体调配物和其用途 |
| TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Ｉｌ-２３拮抗劑於治療感染之用途 |
| CA2678863A1 (en) | 2007-02-23 | 2008-08-28 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| MX2009009079A (es) * | 2007-02-23 | 2009-08-31 | Schering Corp | Anticuerpos anti-il-23p19 de ingenieria. |
| AU2008232903B9 (en) * | 2007-03-30 | 2013-09-05 | Medimmune Llc | Antibodies with decreased deamidation profiles |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| WO2009114040A2 (en) | 2007-09-28 | 2009-09-17 | Centocor Ortho Biotech Inc. | Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| NZ585516A (en) | 2007-12-21 | 2012-07-27 | Hoffmann La Roche | Anti-cd20 antibody formulation |
| SG191639A1 (en) * | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CN102202655B (zh) * | 2008-08-27 | 2013-06-19 | 默沙东公司 | 基因工程抗IL-23p19抗体的冻干制剂 |
| MX2011003013A (es) * | 2008-09-19 | 2011-04-11 | Pfizer | Formulacion liquida estable de anticuerpos. |
| CN104398471A (zh) * | 2008-11-28 | 2015-03-11 | Abbvie公司 | 稳定的抗体组合物和用于稳定其的方法 |
| CA2783715A1 (en) * | 2009-12-29 | 2011-07-07 | F. Hoffmann-La Roche Ag | Novel antibody formulation |
| US9220776B2 (en) * | 2011-03-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| SG11201405475UA (en) * | 2012-03-07 | 2014-10-30 | Cadila Healthcare Ltd | Pharmaceutical formulations of tnf-alpha antibodies |
-
2013
- 2013-09-12 UA UAA201506824A patent/UA117466C2/uk unknown
- 2013-12-09 ES ES13863590T patent/ES2732861T3/es active Active
- 2013-12-09 SI SI201331504T patent/SI2931313T1/sl unknown
- 2013-12-09 BR BR112015013540-4A patent/BR112015013540B1/pt active IP Right Grant
- 2013-12-09 IL IL307581A patent/IL307581A/en unknown
- 2013-12-09 CA CA2894869A patent/CA2894869C/en active Active
- 2013-12-09 SM SM20190414T patent/SMT201900414T1/it unknown
- 2013-12-09 JP JP2015547448A patent/JP6266012B2/ja active Active
- 2013-12-09 US US14/651,946 patent/US20150329632A1/en active Pending
- 2013-12-09 TR TR2019/09584T patent/TR201909584T4/tr unknown
- 2013-12-09 EA EA201591133A patent/EA034616B1/ru unknown
- 2013-12-09 AU AU2013359767A patent/AU2013359767B2/en active Active
- 2013-12-09 PT PT13863590T patent/PT2931313T/pt unknown
- 2013-12-09 PL PL13863590T patent/PL2931313T3/pl unknown
- 2013-12-09 EP EP13863590.9A patent/EP2931313B1/en active Active
- 2013-12-09 MX MX2015007213A patent/MX357936B/es active IP Right Grant
- 2013-12-09 CN CN201380065606.7A patent/CN104870016B/zh active Active
- 2013-12-09 DK DK13863590.9T patent/DK2931313T3/da active
- 2013-12-09 WO PCT/US2013/073825 patent/WO2014093203A1/en not_active Ceased
- 2013-12-09 KR KR1020157018314A patent/KR102004585B1/ko active Active
- 2013-12-09 MY MYPI2015701965A patent/MY187921A/en unknown
- 2013-12-09 RS RS20190822A patent/RS59057B1/sr unknown
- 2013-12-09 LT LTEP13863590.9T patent/LT2931313T/lt unknown
- 2013-12-09 IL IL278295A patent/IL278295B2/en unknown
- 2013-12-09 HR HRP20191137TT patent/HRP20191137T1/hr unknown
- 2013-12-09 HU HUE13863590A patent/HUE045668T2/hu unknown
- 2013-12-09 NZ NZ708443A patent/NZ708443A/en unknown
- 2013-12-09 PE PE2015000925A patent/PE20151524A1/es active IP Right Grant
-
2015
- 2015-06-02 IL IL239150A patent/IL239150B/en active IP Right Grant
- 2015-06-08 PH PH12015501296A patent/PH12015501296B1/en unknown
- 2015-06-10 CL CL2015001608A patent/CL2015001608A1/es unknown
- 2015-06-18 ZA ZA2015/04408A patent/ZA201504408B/en unknown
-
2019
- 2019-06-27 CY CY20191100675T patent/CY1121895T1/el unknown
-
2020
- 2020-12-08 US US17/114,754 patent/US20210188964A1/en active Pending
-
2024
- 2024-01-05 US US18/405,772 patent/US20240239884A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121895T1 (el) | Σκευασματα διαλυματος κατασκευασμενων αντισωματων anti-il-23p19 | |
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| CY2024023I2 (el) | Σημασμενοι αναστολεις ειδικου προστατικου αντιγονου μεμβρανης (psma), η χρηση τους ως παραγοντες απεικονισης και φαρμακευτικοι παραγοντες για την αντιμετωπιση του καρκινου του προστατη | |
| CY1121907T1 (el) | Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων | |
| CY1125241T1 (el) | Υποδορια σκευασματα αντισωματων anti-cd38 και οι χρησεις τους | |
| CY1123256T1 (el) | Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων | |
| CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
| CY1124096T1 (el) | Αντισωματα τα οποια στοχευουν αντιγονο ωριμανσης β-κυτταρων και μεθοδοι χρησης | |
| PH12019501931A1 (en) | Anti-pdl1 antibody formulations | |
| CY1125436T1 (el) | Αναστολεις dna-pk | |
| CY1126819T1 (el) | Σημασμενοι αναστολεις ειδικου προστατικου αντιγονου μεμβρανης (psma), η χρηση τους ως παραγοντες απεικονισης και φαρμακευτικοι παραγοντες για την αντιμετωπιση του καρκινου του προστατη | |
| CY1120529T1 (el) | Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων | |
| CY1120517T1 (el) | Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια | |
| CY1123672T1 (el) | Μεθοδοι αγωγης μιας ταυπαθειας | |
| CR20160270A (es) | ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN | |
| MX2019013670A (es) | Formulaciones de anticuerpos y proteinas. | |
| CL2016002816A1 (es) | Anticuerpos anti-cd 134 (ox40) y usos de los mismos (divisional de sol. n° 631-14). | |
| CL2015002562A1 (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| MX2015017341A (es) | Anticuerpos anti-factor del complemento c1q y uso de los mismos. | |
| MX375020B (es) | Anticuerpos anti-alfa-sinucleina y métodos de uso. | |
| EA201590388A1 (ru) | Способы лечения таупатии | |
| EA201591421A1 (ru) | Препараты полипептида фактора ix | |
| JO3565B1 (ar) | الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها | |
| CY1121105T1 (el) | Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv |